{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:04:04Z","timestamp":1767827044331,"version":"3.49.0"},"reference-count":38,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2017,3,21]]},"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To report MRI outcomes and explore the relationship between clinical remission and MRI inflammation in patients with axial spondyloarthritis (axSpA) from the RAPID-axSpA trial, including radiographic (r-)axSpA and non-radiographic (nr-)axSpA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>RAPID-axSpA (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01087762\">NCT01087762<\/jats:ext-link>) was double-blind and placebo-controlled to week 24, dose-blind to week 48 and open-label to week 204. Patients were randomised to certolizumab pegol (CZP) or placebo. Placebo patients entering dose-blind were rerandomised to CZP. MRIs performed at baseline, weeks 12, 48 and 96 were scored by 2 reviewers independently: Spondyloarthritis Research Consortium of Canada (SPARCC) for sacroiliac (SI) joints; Berlin modification of the Ankylosing Spondylitis spine MRI scoring system for disease activity (Berlin) for spine. Inflammation thresholds: SPARCC\u22652; Berlin&gt;2. Remission thresholds: SPARCC&lt;2 (SI joints); Berlin\u22642 (spine); Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (&lt;1.3, clinical).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Across 163 patients in the MRI set (109 CZP; 54 placebo), week 12 mean changes from baseline in MRI scores were greater for CZP versus placebo: SPARCC: \u22124.8 (SD 8.6) vs \u22121.6 (7.8; p&lt;0.001); Berlin: \u22122.9 (4.2) vs 0.2 (4.8; p&lt;0.001). Improvements were maintained to week 96. Week 12 MRI remission was achieved by 52.6% of patients with baseline MRI inflammation in SI joints, 62.0% in the spine and 37.9% of patients with both. MRI remission rates were sustained to week 96, with similar trends in r-axSpA and nr-axSpA. At week 96, 57.5% vs 65.9% of patients achieving versus not achieving clinical remission had MRI remission.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>CZP reduced inflammation in the spine and SI joints in patients with r-axSpA and nr-axSpA, with improvements maintained over 96\u2005weeks. Substantial proportions of patients achieved MRI remission. Concordance between clinical remission and current definitions of absence of MRI inflammation was limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01087762\" ext-link-type=\"uri\">NCT01087762<\/jats:ext-link>; Post-results.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2017-000430","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T20:10:25Z","timestamp":1493151025000},"page":"e000430","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":34,"title":["Effect of certolizumab pegol over 96\u2005weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis"],"prefix":"10.1136","volume":"3","clinical-trial-number":[{"clinical-trial-number":"nct01087762","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"J\u00fcrgen","family":"Braun","sequence":"first","affiliation":[{"name":"Rheumazentrum Ruhrgebiet, Herne, Germany"}]},{"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[{"name":"Rheumazentrum Ruhrgebiet, Herne, Germany"}]},{"given":"Kay-Geert","family":"Hermann","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Medical School, Berlin, Germany"}]},{"given":"Robert","family":"Landew\u00e9","sequence":"additional","affiliation":[{"name":"Academic Medical Center Amsterdam & Atrium Medical Center Heerlen, Amsterdam, The Netherlands"}]},{"given":"Pedro M","family":"Machado","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology Research & MRC Centre for Neuromuscular Diseases, University College London, London, UK"}]},{"given":"Walter P","family":"Maksymowych","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alberta, Alberta, Alberta, Canada"}]},{"given":"Owen","family":"Davies","sequence":"additional","affiliation":[{"name":"UCB Pharma, Slough, UK"}]},{"given":"Bengt","family":"Hoepken","sequence":"additional","affiliation":[{"name":"UCB Pharma, Monheim, Germany"}]},{"given":"Tommi","family":"Nurminen","sequence":"additional","affiliation":[{"name":"UCB Pharma, Monheim, Germany"}]},{"given":"Christian","family":"Stach","sequence":"additional","affiliation":[{"name":"UCB Pharma, Monheim, Germany"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[{"name":"D\u00e9sir\u00e9e van der Heijde: Leiden University Medical Centre, Leiden, The Netherlands"}]}],"member":"239","published-online":{"date-parts":[[2017,4,24]]},"reference":[{"key":"2025090313193912000_3.1.e000430.1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"2025090313193912000_3.1.e000430.2","first-page":"230","article-title":"Magnetic resonance imaging of sacroiliitis in patients with spondyloarthritis: correlation with anatomy and histology","volume":"186","author":"Hermann","year":"2014","journal-title":"Rofo"},{"key":"2025090313193912000_3.1.e000430.3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00393-011-0894-3","article-title":"[MRI examinations for axial and peripheral spondyloarthritis]","volume":"71","author":"Baraliakos","year":"2012","journal-title":"Z Rheumatol"},{"key":"2025090313193912000_3.1.e000430.4","doi-asserted-by":"crossref","unstructured":"Hamilton L , Barkham N , Bhalla A , et al . BSR and BPHR Guideline for the Treatment of Axial Spondyloarthritis (Including Ankylosing Spondylitis) with Biologics. Rheumatology (Oxford) 2017;56:313\u20136. https:\/\/academic.oup.com\/rheumatology\/article\/56\/2\/313\/2631549\/BSR-and-BHPR-guideline-for-the-treatment-of-axial.","DOI":"10.1093\/rheumatology\/kew223"},{"key":"2025090313193912000_3.1.e000430.5","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000054"},{"key":"2025090313193912000_3.1.e000430.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.24024"},{"key":"2025090313193912000_3.1.e000430.7","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/art.39666","article-title":"Rate and predisposing factors for sacroiliac joint radiographic progression after a two-year follow-up period in recent-onset spondyloarthritis","volume":"68","author":"Dougados","year":"2016","journal-title":"Arthritis Rheum"},{"key":"2025090313193912000_3.1.e000430.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208011"},{"key":"2025090313193912000_3.1.e000430.9","doi-asserted-by":"publisher","DOI":"10.1186\/ar2496"},{"key":"2025090313193912000_3.1.e000430.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.24132"},{"key":"2025090313193912000_3.1.e000430.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200859"},{"key":"2025090313193912000_3.1.e000430.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200208"},{"key":"2025090313193912000_3.1.e000430.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205178"},{"key":"2025090313193912000_3.1.e000430.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203419"},{"key":"2025090313193912000_3.1.e000430.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204231"},{"key":"2025090313193912000_3.1.e000430.16","first-page":"668","article-title":"Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial","volume":"67","author":"Sieper","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025090313193912000_3.1.e000430.17","doi-asserted-by":"crossref","unstructured":"van der Heijde D , Dougados M , Landew\u00e9 R , et al . Long Term Efficacy, Safety and Patient-Reported Outcomes of Certolizumab Pegol in Axial Spondyloarthritis: 4-Year Outcomes from RAPID-axSpA. Rheumatology (Oxford) 2017; in press.","DOI":"10.1093\/rheumatology\/kex174"},{"key":"2025090313193912000_3.1.e000430.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233"},{"key":"2025090313193912000_3.1.e000430.19","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2025090313193912000_3.1.e000430.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.21337"},{"key":"2025090313193912000_3.1.e000430.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.140541"},{"key":"2025090313193912000_3.1.e000430.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.10883"},{"key":"2025090313193912000_3.1.e000430.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1521-6942(02)90250-0"},{"key":"2025090313193912000_3.1.e000430.24","first-page":"862","article-title":"Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment","volume":"34","author":"Lukas","year":"2007","journal-title":"J Rheumatol"},{"key":"2025090313193912000_3.1.e000430.25","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140806"},{"key":"2025090313193912000_3.1.e000430.26","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.100826"},{"key":"2025090313193912000_3.1.e000430.27","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138594"},{"key":"2025090313193912000_3.1.e000430.28","doi-asserted-by":"publisher","DOI":"10.1002\/art.20977"},{"key":"2025090313193912000_3.1.e000430.29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200308"},{"key":"2025090313193912000_3.1.e000430.30","doi-asserted-by":"publisher","DOI":"10.1002\/art.21790"},{"key":"2025090313193912000_3.1.e000430.31","doi-asserted-by":"publisher","DOI":"10.1002\/art.23044"},{"key":"2025090313193912000_3.1.e000430.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.38721"},{"key":"2025090313193912000_3.1.e000430.33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201766"},{"key":"2025090313193912000_3.1.e000430.34","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140056"},{"key":"2025090313193912000_3.1.e000430.35","first-page":"667","article-title":"Spinal inflammation in the absence of sacroiliac joint inflammation on magnetic resonance imaging in patients with active nonradiographic axial spondyloarthritis","volume":"66","author":"van der Heijde","year":"2014","journal-title":"J Rheumatol"},{"key":"2025090313193912000_3.1.e000430.36","doi-asserted-by":"publisher","DOI":"10.1002\/art.33465"},{"key":"2025090313193912000_3.1.e000430.37","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206971"},{"key":"2025090313193912000_3.1.e000430.38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207823"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2017-000430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:19:49Z","timestamp":1756930789000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2017-000430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,4,24]]},"published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1136\/rmdopen-2017-000430"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2017-000430","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}